A recent phase 3 study shows that combining the targeted therapy osimertinib with chemotherapy may revolutionize treatment for patients with advanced EGFR-mutated lung cancer. Investigators report unprecedented survival rates, sparking optimism for significantly improved outcomes in this patient group.

An unexpected symptom like finger clubbing could be a crucial warning sign of lung cancer. Early detection is vital—learn why you should never ignore these signals.